Ulrich G.
- Country
- Germany
- Department
- Hematology, Oncology, Gastroenterology
Research Overview
- An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy (VENAZA-5S PILOT TRIAL)
- Efficacy and Safety of PF-08634404 Plus Combination Therapy Versus Pembrolizumab Plus Combination Therapy in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- MRD-Guided Pembrolizumab and Azacitidine Therapy in NPM1-Mutated Acute Myeloid Leukemia with Imminent Hematological Relapse
Data & Insights
Has run more than one trial at 381 of 718 partner sites.
Specializations
Blood Cancers
Specializes in innovative treatments for multiple myeloma and various forms of leukemia, with particular focus on targeted therapies and immunotherapy approaches.
- Multiple Myeloma Therapeutics
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Acute Lymphoblastic Leukemia
Investigates novel drug combinations including isatuximab, iberdomide, and venetoclax-based regimens.
Lymphoma Studies
Conducts research in various lymphoma subtypes, focusing on novel therapeutic combinations and targeted approaches for both initial treatment and relapsed disease.
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Waldenström's Macroglobulinemia
- Hodgkin Lymphoma
Explores treatment strategies incorporating BTK inhibitors and monoclonal antibodies.
Solid Tumors
Leads research in advanced colorectal and lung cancer treatments, with emphasis on targeted therapies for specific genetic mutations.
- Colorectal Cancer
- HER2+ Metastatic Cancer
- Non-Small Cell Lung Cancer
- ROS1-Positive NSCLC
Investigates organ preservation strategies and molecular-guided treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.